The effectiveness and cost-utility of nasal continuous positive airway pressure (nCPAP) treatment was evaluated in obstructive sleep apnoea syndrome (OSAS), using a 15D health-related quality of life (HRQoL) instrument in a routine clinical setting. In total, 78 OSAS patients (43 receiving nCPAP; 35 receiving lifestyle guidance) were included in the study. nCPAP treatment had a minor effect on the total HRQoL score; only the dimension of sleep improved in both groups. The mean ± SD number of quality-adjusted life years (QALYs) gained was 0.016 ± 2.34 in the nCPAP group and 0.386 ± 1.16 in the lifestyle guidance group. The mean cost per QALY gained was ¤73 375 for the nCPAP group and ¤845 for the lifestyle guidance group. The effect of nCPAP treatment on the HRQoL in a population of unselected OSAS patients was surprisingly small and the cost per QALY gained was high.
Introduction
The relative shortage of resources compared with available treatment options means that comparable cost-effectiveness data are required when making healthcare investment decisions. The effectiveness of treatments, usually characterized using disease-specific indicators, needs to be defined in a way that allows comparison between different medical specialities. Health gains must be expressed in commensurate terms, such as the qualityadjusted life year (QALY), which the UK J Lojander, P Räsänen, H Sintonen et al.
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National Institute of Health and Clinical Excellence has recognized as its principal measure of health outcome. 1 Obstructive sleep apnoea syndrome (OSAS) is a sleep disorder characterized by excessive snoring and periodic breathing with repetitive apnoeas, hypopnoeas and arousals leading to fragmented sleep. It is associated with daytime somnolence and cardiovascular complications. Patients may be personally unaware of their snoring and breathing pauses during sleep, but acutely aware of their consequences in the form of daytime sleepiness, impaired work performance, irritability, marital disharmony and reduced participation in (and enjoyment of) everyday activities. These people have significantly impaired quality of life 2 -4 and social functioning 5,6 and a high prevalence of minor psychiatric morbidity. Nasal continuous positive airway pressure (nCPAP) treatment has been shown to reduce objective sleepiness and improve mood disturbances and cognitive function 2 in both mild and severe disease. However, in addition to treating the site or the consequences of the obstruction itself, the risk factors for OSAS should also be modified. This is usually attempted by lifestyle interventions, encouraging patients to lose weight, avoid sleep deprivation and refrain from tobacco, alcohol and sedatives.
In a study by Young et al., 7 2% of women and 4% of men in the middle-aged work force met the diagnostic criteria for OSAS. Reflecting its potentially high prevalence, the demand for diagnostic and therapeutic services for OSAS has increased markedly during the 1990s. The growing demand and the high cost of treatment have led to OSAS being defined as a priority disease area for health technology assessment. 8, 9 Cost-effectiveness studies allow comparison of the benefits and costs of different treatments. 10 QALYs gained are increasingly used as a measure of effectiveness in such studies, 11, 12 but are often based on economic modelling using health-related quality of life (HRQoL) data obtained from poorly defined sources or estimated by healthcare professionals. Only a limited number of studies have reported QALYs gained based on actual patientreported HRQoL data. 13 In the field of OSAS, cost-effectiveness has been reported in some studies using the standard gamble approach 14, 15 or generic health status questionnaires such as the Nottingham Health Profile. 16 -18 However, these studies did not cover the whole spectrum of the disease and patients with milder forms of OSAS were excluded from the analyses. The true effectiveness of nCPAP treatment on HRQoL under everyday circumstances in a routine clinical setting, when patients are chosen for this treatment using currently accepted criteria, thus remains largely unproven.
In this prospective analysis, the quality of life outcome of OSAS patients treated with either nCPAP or lifestyle guidance was evaluated using the 15D, a generic, selfreported HRQoL questionnaire. 19 or a static charge-sensitive bed and oximetry-based technique. 20 Recordings were performed at home or during overnight stay in the hospital. For patients with a negative routine polygraph result but a suspicion of possible OSAS, a standard polysomnography test was performed (Alice 3; Healthdyne Technologies, Marietta, GA, USA). A diagnosis of OSAS was made on the basis of an apnoea-hypopnoea index (AHI) or 4% oxygen desaturation index (ODI4) ≥ 5 and significant disabling symptoms attributable to OSAS.
Patients and methods

PATIENTS
All subjects gave written informed consent to participate in the study. The Ethical Committee of the Helsinki and Uusimaa Hospital District approved the study protocol.
TREATMENTS
Following a diagnosis of OSAS (AHI or ODI4 ≥ 5) and disabling daytime somnolence, the decision of whether to commence nCPAP therapy or whether to issue lifestyle guidance was made by the physician on the basis of the patient's subjective symptoms and their willingness to undergo nCPAP therapy.
The nCPAP therapy was preceded by a one-night nCPAP titration study using the REMstar ® Auto Smart CPAP System (Respironics Inc., Murrysville, PA, USA). The nCPAP pressure required to cover > 90% of apnoeas was calculated from the titration study and used as the initial setting for the CPAP machine (Sullivan ® V Elite, ResMed, Sydney, Australia). For patients requiring an intolerably high pressure (> 10 cmH 2 O), autoCPAP (AutoSet Spirit™, ResMed) or a bilevel device (Breas PV-101™, Breas Medical, Mölnlycke, Sweden) was used. All devices were provided by the local healthcare system.
Fitting of appropriate masks and demonstration of the use of the CPAP machines was performed by an experienced nurse whom the subjects were then encouraged to contact or call in case of any difficulties. Compliance (usage hours on the nCPAP counter) was monitored during a scheduled visit 3 months after the start of therapy. In addition to nCPAP treatment, patients received standard verbal advice on a weight-reducing diet, nasal steroids, avoidance of alcohol or sedatives at bedtime and avoidance of sleeping supine.
The conservatively treated control group (lifestyle guidance group) received similar standard verbal advice only. No follow-up visits were scheduled for the lifestyle group. Neither group received any surgical intervention during the study period.
All patients received their previously scheduled routine treatment.
QUALITY OF LIFE QUESTIONNAIRE
All referred patients received the 15D HRQoL questionnaire with the letter of invitation to attend the hospital. Those who agreed to participate and returned the questionnaire were sent the same questionnaire again approximately 6 months later.
The 15D is a generic, 15-dimensional, standardized, self-administered instrument that can be used both as a profile and a single index score measure. 21 It covers 15 dimensions: moving, seeing, hearing, breathing, sleeping, eating, speech, elimination, usual activities, mental function, discomfort and symptoms, depression, distress, vitality and sexual activity. For each dimension, the respondent must score them on a 1 -5 rating system (best = 1, worst = 5) that most accurately describes his or her state of health at that time. Valuation of the 15D is based on an application of the multi-attribute utility theory, where a set of utility or preference weights, elicited through a three-stage valuation procedure, is used in an additive J Lojander, P Räsänen, H Sintonen et al.
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aggregation formula to generate the 15D score (a single index number) across all the dimensions. 22 The maximum score is 1 (no problems on any dimension) and the minimum score is 0 (equivalent to being dead). In most of the important properties, the 15D is comparable with other instruments of its kind. 23 -25 Results were compared with findings from members of the Finnish general population, matched for age and sex, obtained from the Health 2000 Health Examination Survey. 26 
ANALYSIS OF COSTS
Costs were analysed from the perspective of the provider of secondary healthcare services. Direct hospital costs were obtained from the Ecomed ® clinical patient administration system (Datawell Ltd, Espoo, Finland), where data on all costs of hospital treatment of individual patients are routinely stored. All relevant specialtyrelated costs (nCPAP devices, polygraph recordings, ambulatory visits, laboratory investigations and radiographic examinations), including pre-and postintervention outpatient visits to the hospital, were analysed. Direct patient costs and productivity costs due to possible absence from work were not included.
The HRQoL gain representing the utility of the intervention was assumed to last until the end of the remaining statistical life expectancy of each patient. 27 Although this may not always be strictly true, this approach is typically used for the calculation of QALYs gained by medical interventions. Dividing costs by the number of QALYs gained gave the incremental cost-utility ratio compared with the hypothetical situation, where no specific treatment would have been provided, in terms of cost per QALY gained. As the benefit of treatment was expected to last for many years, whereas the costs were accrued only during the study period, the number of QALYs and consequent data on cost per QALY were reported using a discount rate of 5%. Sensitivity analyses were performed using discount rates varying between 1% and 5%. The upper and lower 95% confidence intervals for the mean differences in treatment effectiveness (HRQoL change) and costs were also calculated.
STATISTICAL ANALYSIS
For the 15D questionnaire, a minimal important difference ≥ 0.03 was considered to be clinically significant. 23, 28 Statistical analysis was performed on the basis of intention-to-treat. Data were analysed using the SPSS ® for Windows ® statistical software, version 11.0 (SPSS Inc., Chicago, IL, USA). Results were given as the mean ± SD or as the mean and 95% confidence interval. For continuous variables, the significance of the differences between the groups was analysed using one-way analysis of variance followed by post-hoc comparisons with an independent samples t-test. When comparing percentage distributions between the groups, the χ 2 test was used. Differences between before-and after-treatment scores were analysed using the Student's paired t-test for dependent samples. A P-value < 0.05 was considered to be statistically significant.
Results
A total of 172 patients had verified OSAS on the basis of the polygraph recording (AHI or ODI4 ≥ 5) and significant disabling symptoms, and were asked to fill in the 15D questionnaire. Of these, 78 completed and returned both of the 15D questionnaires that were sent to them and were included in further analysis. Baseline data for the patients in the nCPAP and lifestyle guidance groups are shown in Table 1 . Baseline J Lojander, P Räsänen, H Sintonen et al. Continuous positive airway pressure therapy in sleep apnoea characteristics (age, body mass index AHI, ODI4 and ESS) did not differ between the patients who responded to the questionnaire and those who did not (data not shown).
Therapy with nCPAP was started in 43 patients; of these, 33 were still continuing with therapy at the time of the second questionnaire. Of the 10 patients who stopped, three were unable to continue with nCPAP after the first night and seven discontinued therapy because of nasal problems and/or poor compliance (usage < 1 h/night). They were, nevertheless, included in the nCPAP group in the intention-to-treat analysis. The lifestyle guidance group consisted of 35 patients. The median time between answering the two questionnaires was 6.8 months (range 6.2 -10.7 months). Compliant patients in the nCPAP group had been using their devices a median of 4.9 months (range 1.2 -9 months) before the second evaluation. For the compliant patients continuing on therapy, median usage recorded from the device counter of nCPAP was 4 h/night (range 1.5 -8.8 h/night).
CHANGE IN QUALITY OF LIFE
The 15D profiles of the nCPAP group at baseline and those of the Finnish general population matched for age and sex are shown in Fig. 1 . The mean baseline 15D score was statistically and clinically significantly lower in the study patients, especially in the nCPAP group (0.84 compared with 0.91 for the nCPAP group and general population [P < 0.001], respectively). Furthermore, the baseline 15D score was worse, but not significantly so, in the nCPAP group (0.84) than in the lifestyle guidance group (0.88). At the 6 month follow-up, the mean 15D score had improved only a little in the lifestyle guidance group (from 0.88 to 0.90) and practically not at all in the nCPAP group (from 0.84 to 0.85); neither of these differences were statistically significant. Of the dimensions covered by the 15D questionnaire, sleeping had improved in a statistically significant manner (P = 0.04) in the nCPAP group and both sleeping (P = 0.001) and vitality (P = 0.046) had improved significantly in the lifestyle group (Fig. 2) .
Analysis of the subgroup of patients with nCPAP usage of at least 6 h/night did not change the outcome in favour of nCPAP treatment (data not shown).
Lifestyle guidance group CPAP group (n = 35) (n = 43)
Sex Male  26  29  Female  9 14 Age (years) 56.6 ± 9.9 55.4 ± 10.5 Apnoea-hypopnoea index 19.9 ± 10.1 32.1 ± 19.9 a 4% oxygen desaturation index 10.7 ± 9.6 22.9 ± 19.9 a Epworth Sleepiness Scale score 5.5 ± 2.9 6.1 ± 3.1 Body mass index (kg/m 2 )
28.5 ± 5.0 31.9 ± 6.5 a 15D score 0.88 ± 0.10 0.84 ± 0.11
Values are the mean ± SD. a P < 0.05 compared with lifestyle guidance group. 
QALYS AND COSTS
The mean ± SD number of QALYs gained was 0.016 ± 2.34 in the nCPAP group and 0.386 ± 1.16 in the lifestyle guidance group.
The mean ± SD total costs per patient were higher in the nCPAP group (€1174 ± 596) than in the lifestyle guidance group (€326 ± 311). Six patients incurred additional costs due to requiring polysomnography for confirmation of the diagnosis of OSAS (€370 per recording). More expensive autoCPAP devices (€580 per device) and bi-level devices (€1414 per device) were required in four and three patients, respectively. These additional costs are included in the above-mentioned mean ± SD total costs per patient.
The mean cost per QALY gained was €73 375 for the nCPAP group and €845 for the lifestyle guidance group. The results of the sensitivity analysis, in which the cost per QALY was analysed using various discount rates and varying the effectiveness and cost of treatment within the 95% confidence interval of the means observed in the study, are shown in Table 2 . 
Discussion
Although earlier controlled studies have shown that nCPAP treatment is efficacious in selected sleep apnoea patients, 11, 17, 29 the true effectiveness of this treatment under everyday conditions has so far remained largely unproven. The strength of the present study is that it provides data on the effectiveness and costs of normal routine hospital practice, when patients are treated under currently accepted indication criteria and guidelines within the ordinary routine of a large university hospital. Furthermore, as the findings are based on unselected material, unlike most randomized or controlled clinical trials, they also reflect the true everyday effectiveness of treatments.
Another strength of the current study is that the estimate of utility is based on patientreported outcome, whereas traditionally many evaluations of medical therapy have tended to use objective endpoints with little relevance to patient-perceived benefits of treatment. In our sample, patients with OSAS had a clearly lower HRQoL than ageand gender-matched controls from the general Finnish population. This is in accordance with earlier findings from Austria. 30 In light of the fact that the nCPAP patients were, according to self-reported HRQoL, clearly affected by their disease, the minimal effect of treatment is rather surprising. That the study population was unselected and included patients with milder disease may help to explain the disappointing result. However, even patients with milder disease have been reported to benefit from treatment 31 and current guidelines support the use of nCPAP therapy for OSAS of any AHI severity, provided that the patient suffers from symptoms of sleepiness than can be defined as more severe than 'mild'. In the present study the choice of treatment modality was based on current guidelines, but most patients experienced only minimal subjective improvement from nCPAP therapy and a significant number of patients failed to use the therapy at all. This suggests that the current criteria may not be optimal for the selection of patients who will benefit from this treatment.
The results of the present study are in contrast to some earlier studies in similar settings in which the benefit of nCPAP was clear; 11, 17, 29, 32 however, opposite results have also been reported. For example, in a wellplanned randomized study by Profant et al., 33 patients in both the control group and the nCPAP group showed only minor improvement in quality of life. In the study by Bolitscheck et al., 30 OSAS patients benefited from nCPAP when evaluated using other criteria, but failed to show an improvement in HRQoL.
It is still controversial how much nCPAP is needed to abolish OSAS symptoms. In the study by Meslier et al., 32 patients who used nCPAP for at least 4 h/night received satisfactory benefit. In the present study, patients in the nCPAP group used their device on average for 4 h/night and for at least 1.5 h/night. Analysis of the subgroup of patients with nCPAP usage of at least 6 h/night did not alter the outcome in favour of nCPAP treatment. These results may indicate the inability of nCPAP to reverse all of the symptoms of OSAS, however, a real negative effect of nCPAP, at least in the first months of treatment, cannot be ruled out. Nasal problems and general inconvenience are well known side-effects of nCPAP therapy. 34 In the present study, most nCPAP users had at least minor problems during the first months of treatment, despite the use of autoCPAP or bi-level CPAP devices when necessary.
The small positive effect of lifestyle guidance was slightly unexpected, however the study groups were not randomized and were, therefore, not identical. The OSAS patients in the lifestyle group had milder disease as indicated by the significantly lower AHI and ODI4 values at baseline compared with patients treated with nCPAP; they also had a slightly higher (though not statistically significant) HRQoL score. The clinical intervention of making the diagnosis and the conservative management guidance might have led to a positive effect on these OSAS patients, especially those with milder disease. In two other nCPAP treatment studies, 14, 35 the number of QALYs gained with the therapy ranged between 0.013 and 0.12 and 0.113 and 0.367. In the present study the mean number of QALYs gained was at a similar level (0.386) in the lifestyle guidance group, but was only 0.016 in the nCPAP group.
There are currently several HRQoL questionnaires available for clinical studies, some of which have been compared in clinical studies evaluating OSAS patients. 15, 18 Although the generic 15D questionnaire used in the present study has not been tested in sleep apnoea patients, it is well validated and has been successfully used in many other clinical studies, including those evaluating asthmatic patients, 22,23,36 orthopaedic patients, 37 back-pain patients 38 and cataract patients. 39 It, therefore, seems unlikely that the method of collecting the HRQoL data itself could explain the rather modest improvement in the total score in the nCPAP or lifestyle guidance groups. Statistically significant improvement, compared with baseline, was only seen in the dimension of sleeping in both groups and additionally in the dimension of vitality in the lifestyle group.
In conclusion, the results of the present study confirm earlier findings that patients with OSAS have a clearly reduced HRQoL score compared with the general population. Treatments provided for these patients under everyday circumstances, in a routine clinical setting and chosen using currently accepted criteria, showed only a modest effect on HRQoL. These results indicate that nCPAP treatment may not inevitably be superior to lifestyle guidance for unselected OSAS patients and stress the importance of redefining the patient selection criteria.
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